Weiss Multi-Strategy Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,910	Closed	-$1.28M	–	504
2023 Q4	$1.28M	Sell	17,910 -163	-0.9%	-$9.38K	0.03%	410
2023 Q3	$941K	Sell	18,073 -615	-3%	-$35.8K	0.02%	437
2023 Q2	$1.18M	Sell	18,688 -1,951	-9%	-$122K	0.02%	527
2023 Q1	$1.12M	Buy	20,639 +1,606	+8%	+$77.6K	0.03%	501
2022 Q4	$1.01M	Sell	19,033 -467	-2%	-$23.4K	0.03%	463
2022 Q3	$907K	Sell	19,500 -595	-3%	-$31.1K	0.02%	502
2022 Q2	$1.15M	Sell	20,095 -638	-3%	-$36.2K	0.03%	466
2022 Q1	$1.27M	Buy	20,733 +836	+4%	+$43.4K	0.03%	467
2021 Q4	$1.04M	Sell	19,897 -1,353	-6%	-$56.8K	0.02%	469
2021 Q3	$792K	Buy	21,250 +461	+2%	+$16K	0.02%	509
2021 Q2	$849K	Buy	20,789 +742	+4%	+$27.4K	0.02%	507
2021 Q1	$680K	Sell	20,047 -4,728	-19%	-$164K	0.01%	525
2020 Q4	$788K	Sell	24,775 -7,790	-24%	-$205K	0.02%	516
2020 Q3	$836K	Buy	32,565 +10,127	+45%	+$231K	0.02%	443
2020 Q2	$576K	Buy	22,438 +770	+4%	+$15.6K	0.02%	459
2020 Q1	$333K	Sell	21,668 -8,332	-28%	-$181K	0.01%	368
2019 Q4	$1.03M	Hold	30,000	–	–	0.02%	488
2019 Q3	$224K	Hold	30,000	–	–	﹤0.01%	540
2019 Q2	$389K	Hold	30,000	–	–	0.01%	439
2019 Q1	$365K	Hold	30,000	–	–	0.01%	457
2018 Q4	$342K	Sell	30,000 -30,205	-50%	-$488K	0.01%	378
2018 Q3	$1.31M	Sell	60,205 -14,795	-20%	-$309K	0.03%	374
2018 Q2	$1.32M	Sell	75,000 -20,000	-21%	-$406K	0.03%	407
2018 Q1	$2M	Sell	95,000 -10,000	-10%	-$195K	0.06%	322
2017 Q4	$1.52M	Buy	105,000 +300	+0.3%	+$4.63K	0.04%	384
2017 Q3	$1.65M	Sell	104,700 -11,300	-10%	-$166K	0.06%	332
2017 Q2	$1.44M	Buy	116,000 +36,000	+45%	+$417K	0.06%	330
2017 Q1	$1.3M	Sell	80,000 -100,000	-56%	-$1.45M	0.05%	356
2016 Q4	$2.72M	Buy	180,000 +165,000	+1,100%	+$2.33M	0.13%	163
2016 Q3	$229K	Sell	15,000 -32,385	-68%	-$1.31M	0.01%	391
2016 Q2	$1.84M	Sell	47,385 -109,115	-70%	-$3.92M	0.14%	200
2016 Q1	$4.35M	Buy	156,500 +42,500	+37%	+$1.42M	0.19%	149
2015 Q4	$6.13M	Hold	114,000	–	–	0.42%	51
2015 Q3	$4.57M	Buy	114,000 +94,000	+470%	+$3.07M	0.2%	104
2015 Q2	$639K	Sell	20,000 -60,000	-75%	-$1.52M	0.03%	356
2015 Q1	$1.91M	Buy	80,000 +55,000	+220%	+$1.23M	0.08%	248
2014 Q4	$441K	Sell	25,000 -32,945	-57%	-$515K	0.02%	347
2014 Q3	$794K	Hold	57,945	–	–	0.02%	404
2014 Q2	$977K	Buy	+57,945	New	+$958K	0.02%	421

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Weiss Multi-Strategy Advisers's ITCI Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 17,910 shares — an estimated $1.28M sold.

Weiss Multi-Strategy Advisers first reported a position in ITCI in Q2 2014 and held it in 39 quarters. The position peaked at $6.13M in Q4 2015. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 17,910 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $1.28M.
Weiss Multi-Strategy Advisers first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 39 quarters.
Weiss Multi-Strategy Advisers's Intra-Cellular Therapies Inc. position peaked at $6.13M in Q4 2015.
346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.